[1]丁　洁,李阿利,李　静.血清CCL18与TM4SF1水平检测在卵巢良恶性肿瘤鉴别诊断中的价值研究[J].现代检验医学杂志,2021,36(04):93-95.[doi:10.3969/j.issn.1671-7414.2021.04.019]
　DING Jie,LI A-li,LI Jing.Research on the Value of Detection of the Serum CCL18 and TM4SF1Levels in Differential Diagnosis of Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2021,36(04):93-95.[doi:10.3969/j.issn.1671-7414.2021.04.019]
点击复制

血清CCL18与TM4SF1水平检测在卵巢良恶性肿瘤鉴别诊断中的价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年04期
页码:
93-95
栏目:
论　著
出版日期:
2021-07-31

文章信息/Info

Title:
Research on the Value of Detection of the Serum CCL18 and TM4SF1Levels in Differential Diagnosis of Benign and Malignant Ovarian Tumors
文章编号:
1671-7414（2021）04-093-04
作者:
丁　洁; 李阿利; 李　静
（中国人民解放军联勤保障部队第九八七医院妇产科, 陕西宝鸡 721000）
Author(s):
DING Jie;  LI A-li;  LI Jing
（Department of Obstetrics and Gynecology, No. 987 Hospital of the Joint Service Support Force of the People’sLiberation Army, Shaanxi Baoji 721000, China）
关键词:
卵巢良恶性肿瘤; 血清趋化因子配体18; 血清四次跨膜蛋白1; 鉴别诊断
分类号:
R737.31；R730.43
DOI:
10.3969/j.issn.1671-7414.2021.04.019
文献标志码:
A
摘要:
目的　研究血清趋化因子配体18（chemokine ligand 18，CCL18）与四次跨膜蛋白1（transmembrane-4-L-sixfamily-member-1，TM4SF1）水平检测在卵巢良恶性肿瘤鉴别诊断中的应用价值。方法　收集中国人民解放军联勤保障部队第九八七医院妇产科自2018 年7 月～ 2020 年7 月收治的84 例卵巢肿瘤患者作为研究对象，患者均接受血清CCL18 和TM4SF1 检测。比较良性肿瘤与恶性肿瘤血清CCL18 和TM4SF1 水平，分析血清CCL18 和TM4SF1 鉴别良恶性卵巢肿瘤的价值。结果　84 例卵巢肿瘤患者中良性和恶性分别为48 例和36 例。良性肿瘤与恶性肿瘤患者血清CCL18，TM4SF1 水平比较，差异均有统计学意义（t=9.05，6.42，均P<0.05）。受试者工作曲线（receiver operatingcharacteristic，ROC）分析显示血清CCL18 和血清TM4SF1 联合预测概率判断卵巢恶性肿瘤的曲线下面积（area undercurve，AUC）为0.85，显著高于血清CCL18 和血清TM4SF1 单项检测，差异有统计学意义（P<0.05）。结论　血清CCL18 和TM4SF1 联合检测有助于鉴别卵巢良恶性肿瘤。

参考文献/References:

[1] 马欢, 田小飞, 李红霞. 复发性卵巢癌患者血清NDRG4 水平表达与临床特征及预后的相关性研究[J]. 现代检验医学杂志,2019,34(5):81-83.MA Huan,TIAN Xiaofei,LI Hongxia.Correlationbetween serum NDRG4 expression and clinical featuresand prognosis in patients with recurrent ovariancancer[J].Journal of Modern Laboratory Medicine,2019,34(5):81-83.
[2] 付妮娜, 范婧晖, 钟慧.CA125,HE4 和MMP7 联合检测在Ⅰ型和Ⅱ型上皮性卵巢癌患者诊断中的价值[J]. 现代检验医学杂志,2019,34(6):109-112,156.FU Nina, FAN Jinghui, ZHONG Hui.Diagnostic valueof combined detection of CA125, HE4 and MMP7 intype Ⅰ and Ⅱ epithelial ovarian cancer[J]. Journal ofModern Laboratory Medicine,2019,34(6):109-112,156.
[3] 张善弟, 荆成宝, 禹梅. 血清CEA,CA125 和HE4联合检测对卵巢癌的诊断价值[J]. 现代检验医学杂志,2018,33(6):122-124,131.ZHANG Shandi, JING Chengbao,YU Mei.Clinicalvalue of combined detection of serum CEA,CA125 andHE4 in the diagnosis of ovarian cancer[J]Journal ofModern Laboratory Medicine,2018,33(6):122-124,131.
[4] 马同敏, 赵志强. 血清CA125,STIP1 和IGF- Ⅰ联合检测对卵巢癌的早期诊断价值研究[J]. 现代检验医学杂志,2018,33(6):50-54,58.MA Tongmin, ZHAO Zhiqiang.Clinical value of combineddetection of serum CA125,STIP1 and IGF-Ilevels in early diagnosis of ovarian cancer[J].Journal ofModern Laboratory Medicine,2018,33(6):50-54,58.
[5] 李玲, 罗雅文, 何霞, 等. 子宫内膜癌患者BMI 与血清HE4,CA125 联合检测的诊断价值[J]. 现代检验医学杂志,2018,33(5):91-94.LI Ling, LUO Yawen,HE Xia,et al.Diagnostic valueof combined detection of body mass index andserum HE4,CA125 in patients with endometrialcarcinoma[J].Journal of Modern Laboratory Medicine,2018,33(5):91-94.
[6] 赵枰, 洪煜婧, 陈相, 等. 上皮性卵巢癌患者外周血循环肿瘤细胞检测的临床意义[J]. 现代检验医学杂志, 2017,32(4):50-51,56.ZHAO Ping, HONG Yujing, CHEN Xiang,et al.Clinicalsignificance of circulating tumor cells detection fromperipheral blood of patients with epithelial ovariancancer[J]. Journal of Modern Laboratory Medicine,2017,32(4):50-51,56.
[7] 郑福利, 党淼, 张淼芳, 等. 子宫内膜癌组织中趋化因子CXCL12 及其受体 CXCR4 表达水平研究[J].现代检验医学杂志,2015,30(4):21-23,27.ZHENG Fuli, DANG Miao, ZHANG Miaofang,etal.Expression of chemokine CXCL12 and its receptorCXCR4 in endometrial carcinoma tissues[J]. Journal ofModern Laboratory Medicine,2015,30(4):21-23,27.
[8] 姚红羽, 阳志军.TM4SF1 在恶性肿瘤研究中的进展[J]. 医学与哲学,2018,39(6):60-63.YAO Hongyu, YANG Zhijun. Progress of TM4SF1in malignant tumours[J].Medicine & Philosophy,2018,39(6):60-63.
[9] 中国抗癌协会妇科肿瘤专业委员会, 等. 卵巢恶性肿瘤诊断与治疗指南( 第四版)[J]. 中国实用妇科与产科杂志, 2018,34(7):739-749.Gynecological Cancer Committee of China AntiCancer Association.Guidelines for the diagnosis andtreatment of ovarian malignancies (4th Edition)[J].ChineseJournal of Practical Gynecology and Obstetrics,2018,34(7):739-749.
[10] 洪宏, 袁建芬, 喻海忠. 乳腺癌患者血清长链非编码RNA ATB 表达水平检测及临床诊断价值[J]. 现代检验医学杂志,2020,35(2):22-23,31.HONG Hong,YUAN Jianfen, YU Haizhong. Detectionand clinical diagnosis value of serum long non-codingRNA ATB in patients with breast cancer[J]. Journal ofModern Laboratory Medicine,2020,35(2):22-23,31.
[11] 刘艺璇, 戴岚, 谢蕾, 等.S1P/S1PR 对人卵巢癌SKOV3 细胞的促血管生成作用的研究[J]. 国际妇产科学杂志,2018,45(3):337-341.LIU Yixuan, DAI Lan, XIE Lei,et al.Study on effect ofS1P/S1PR on angiogenesis in SKOV3 ovarian cancercells[J]. Journal of International Obstetrics and Gynecology,2018,45(3):337-341.
[12] 邢瑞青, 吴永昌, 陈慧昱, 等. 血清CA125,HE4 及ROMA 指数对卵巢癌诊断价值的临床研究[J]. 现代检验医学杂志, 2016, 31(6):37-40,43.XING Ruiqing, WU Yongchang, CHEN Huiyu,et al.Diagnosticvalue of serum CA125, HE4 and ROMA indexin patients with ovarian cancer[J]. Journal of ModernLaboratory Medicine,2016, 31(6):37-40,43.
[13] 闫先侠, 孙晓, 张华, 等. 血清人附睾蛋白4 联合CA125 检测在卵巢癌诊断中的应用[J]. 现代检验医学杂志,2015,30(1):134-136.YAN Xianxia, SUN Xiao, ZHANG Hua,et al.Applicationof serum human epididymis protein 4 combined with CA125 in the diagnosis of ovarian cancer[J].Journal of ModernLaboratory Medicine,2015,30(1):134-136.
[14] WEI Yunhai, SHEN Xiaoying , LI Liqin, et al. TM4SF1inhibits apoptosis and promotes proliferation, migrationand invasion in human gastric cancer cells[J].OncolLett, 2018,16(5):6081-6088.
[15] PARK Y R, KIM S L, LEE M R , et al. MicroRNA-30a-5p (miR-30a) regulates cell motility and EMTby directly targeting oncogenic TM4SF1 in colorectalcancer[J]. J Cancer Res Clin Oncol, 2017,143(10):1915-1927.
[16] YE Lin, PU Chunyun, TANG Jun, et al. Transmembrane-4 L-six family member-1 (TM4SF1) promotesnon-small cell lung cancer proliferation, invasion andchemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis[J]. Respir Res, 2019, 20(1):106.
[17] 朱军义, 郭哲, 王双双, 等.MiR-139-5p 通过靶向NFAT 抑制卵巢癌SKOV3 细胞的生长、集落形成、侵袭和迁移[J]. 临床与病理杂志,2020,40(4):807-813.ZHU Junyi, GUO Zhe, WANG Shuangshuang,etal.MiR-139-5p inhibits the growth, colony formation,invasion and migration of ovarian cancer SKOV3 cellsby targeting NFAT[J].International Journal of Pathologyand Clinical Medicine,2020,40(4):807-813.
[18] 赵冰冰, 阳志军, 王琪, 等. 多指标联合检测的液态悬浮芯片技术在卵巢恶性肿瘤诊断中的应用[J]. 中华妇产科杂志,2017,52(1):11-19.ZHAO Bingbing, YANG Zhijun, WANG Qi,et al.Clinicalvalidation of multiple biomarkers suspension arraytechnology for ovarian cancer[J].Chinese Journal ofObstetrics and Gynecology,2017,52(1):11-19.
[19] 高娜娜. CCL18 表达与卵巢癌预后的临床分析[J].实用肿瘤杂志, 2016, 31(5):446-449.GAO Na’na.Expression of CCL18 in ovarian cancerand its relation to prognosis[J].Journal of Practical Oncology,2016, 31(5):446-449.

备注/Memo

备注/Memo:
作者简介：丁洁（1978-），女，本科，主治医师，研究方向：妇产科，E-mail:baojidingjie@163.com。
通讯作者：李阿利，女，本科，主治医师，研究方向：妇科肿瘤，E-mail:312540153@qq.com。
更新日期/Last Update: 1900-01-01